Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. (HOOK) has described itself as a clinical-stage biopharmaceutical company developing next generation immunotherapeutics based on a proprietary arenavirus platform. Its news flow has highlighted programs in oncology and serious infectious diseases, including product candidates targeting HPV16-positive cancers, KRAS mutated cancers, and viral infections such as hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
Company press releases provide detailed updates on its collaboration and license agreement with Gilead Sciences, Inc. For example, HOOKIPA has reported on the HB-400 program in clinical development for HBV and the HB-500 program, a next-generation therapeutic vaccine being evaluated as a potential component of a curative regimen for HIV. News items have described clinical milestones such as enrollment completion in a Phase 1b trial of HB-500, including trial design elements and the intended role of HB-500 in a combination strategy for a potential functional cure of HIV.
HOOKIPA’s news coverage has also included significant corporate and strategic developments. In early 2025, the company issued multiple announcements related to a potential all-share combination with Poolbeg Pharma plc and associated U.K. Takeover Code disclosure requirements, followed by a Rule 2.8 statement that it did not intend to make an offer under Rule 2.7 of the Code. Subsequent releases detailed an asset purchase agreement with Gilead for HOOKIPA’s HB-400 program assets and certain HB-500 assets, and explained how this transaction related to the company’s long-term prospects and strategies.
Later announcements document HOOKIPA’s intention to voluntarily delist its common stock from the Nasdaq Capital Market, deregister its common stock under the Securities Exchange Act of 1934, and seek stockholder approval for dissolution and liquidation. Investors using this news page can review the sequence of clinical updates, collaboration news, U.K. takeover-related disclosures, and corporate actions such as the asset sale to Gilead, the special meeting of stockholders, and the steps toward delisting and deregistration. This provides a consolidated view of both scientific progress and material corporate events affecting HOOKIPA and the HOOK symbol.
HOOKIPA Pharma announced the closing of its underwritten public offering, raising approximately $80.9 million through the sale of 3,910,000 shares of common stock at $11.75 each and 2,978 shares of Series A convertible preferred stock at $11,750 each. The preferred shares are convertible into 1,000 common shares. The offering was managed by Morgan Stanley and SVB Leerink, with RBC Capital Markets as lead manager. Proceeds will likely support HOOKIPA's development of immunotherapeutics targeting infectious diseases and cancers.
HOOKIPA Pharma has announced a public offering of 3,400,000 shares of common stock priced at $11.75 each and 2,978 shares of Series A convertible preferred stock at $11,750 each, aiming to raise approximately $75 million. The offering is set to close on December 11, 2020. The underwriters have an option to purchase an additional 510,000 shares. The funds are intended for advancing its proprietary arenavirus platform targeting infectious diseases and cancers. This offering is made under a shelf registration statement with the SEC.
HOOKIPA Pharma announced an underwritten public offering of its common stock and Series A convertible preferred stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the offered shares. The offering is subject to market conditions, with no assurance regarding its completion or terms. Morgan Stanley and SVB Leerink serve as joint book-running managers. HOOKIPA is a clinical-stage biopharmaceutical company focused on immunotherapeutics targeting infectious diseases and cancers through its proprietary arenavirus platform.
HOOKIPA Pharma announced interim Phase 1 data for HB-201, a replicating monotherapy targeting HPV16-positive cancers. In a trial with 22 enrolled patients, 15 were evaluable, showing an 18% unconfirmed response rate in head and neck cancer patients who had previously received PD1 inhibitors. The treatment demonstrated a 73% disease control rate. Median progression-free survival is currently 72 days. Safety data indicated that 41% experienced treatment-related adverse events, primarily mild. HOOKIPA plans to explore further combination therapies.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported promising interim data for its CMV vaccine candidate HB-101, showing a 48% reduction in CMV viremia and no CMV disease in vaccinated kidney transplant recipients. The Phase 2 trial demonstrated a positive safety profile with a low incidence of side effects. Among the 41 participants, those receiving three doses had significantly better outcomes compared to the placebo group. The company is optimistic about progressing toward a Phase 3 trial, highlighting the vaccine's potential to address a critical unmet need in transplant care.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported its Q3 2020 financial results, revealing revenue of $4.0 million, up from $2.0 million in Q3 2019, primarily due to higher collaborations with Gilead. However, R&D expenses increased to $16.0 million from $11.0 million, contributing to a net loss of $13.6 million, compared to $11.4 million in the prior year. The company continues its clinical development, including the HB-201 and HB-202 oncology candidates, and is optimistic about upcoming efficacy data.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced their participation in two virtual investor conferences: the SVB Leerink Oncology 1x1 Day on November 19, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. The company is focused on developing a new class of immunotherapeutics using their proprietary arenavirus platform. Their ongoing research includes a Phase 2 clinical trial for a CMV vaccine for kidney transplant patients and collaborations with Gilead Sciences for HIV and Hepatitis B treatments.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020, before the market opens. Notably, the company will not hold a conference call for this earnings release, with plans to conduct such calls only alongside its fourth-quarter earnings.
HOOKIPA develops immunotherapeutics utilizing its proprietary arenavirus platform, aiming for innovative treatments in infectious diseases and oncology.
HOOKIPA Pharma has announced the first patient dosed with HB-202, an alternate vector therapy for HPV16+ cancers in its ongoing Phase 1/2 trial. The HB-202/HB-201 regimen aims to enhance immune response, with pre-clinical studies showing a ten-fold increase. This addition could significantly impact treatment options for patients with treatment-refractory HPV16+ cancers. The trial's primary endpoint is safety and tolerability, with preliminary data expected in late 2020 or early 2021.
HOOKIPA Pharma (NASDAQ: HOOK) announced the appointment of Professor Jean-Charles Soria to its Board of Directors. Recognized for his expertise in oncology and immunotherapy, Soria's addition is expected to enhance the scientific diversity of the board and support the company’s expansion of its clinical pipeline. Soria has extensive experience, including leadership roles at Gustave Roussy Cancer Center and AstraZeneca. HOOKIPA is focusing on developing immunotherapeutics targeting infectious diseases and cancers through its proprietary arenavirus platform.
FAQ
What is the current stock price of Hookipa Pharma (HOOK)?
What is the market cap of Hookipa Pharma (HOOK)?
